Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.46 |
| ▸ | CASP1 | P29466 | 2/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | IGF1R | P08069 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.41 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10120310 | 0.90 | GAA (0.49) | ALDH1A1GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL10120312 | 0.87 | ALOX5 (0.46) | ALDH1A1GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL10120622 | 0.79 | GAA (0.50) | ALDH1A1GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL10120096 | 0.79 | GAA (0.50) | ALDH1A1GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL15179288 | 0.78 | ALOX5 (0.47) | ALDH1A1GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL15179400 | 0.78 | KDM4E (0.48) | ALDH1A1GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL10120311 | 0.78 | GAA (0.47) | ALDH1A1GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL10120319 | 0.78 | GAA (0.45) | ALDH1A1GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL10120619 | 0.78 | ALOX5 (0.46) | ALDH1A1GAAKDM4EHPGDHSD17B10 | |
| SCHEMBL15179462 | 0.78 | ALOX5 (0.46) | ALDH1A1GAAKDM4EHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2601194-B1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME (US) | 2016-05-25 | — | — | EP | disclosed |
| US-8871929-B2 | Fused-imidazoyl compounds useful as antimicrobial agents | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871929-B2 | Fused-imidazoyl compounds useful as antimicrobial agents | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MERCK SHARP & DOHME LLC | 2013-08-15 | — | — | US | disclosed |
| WO-2012018662-A2 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | SCHERING CORPORATION (US) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130210816-A1 | FUSED-IMIDAZOYL COMPOUNDS USEFUL AS ANTIMICROBIAL AGENTS | MRPL21, ARG1, RPS4Y1 | ALDH1A1 2376/4885GAA 2781/4885KDM4E 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.